Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dehmer SP, Maciosek MV, Flottemesch, TJ. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis. Rockville: Agency for Healthcare Research and Quality (AHRQ). AHRQ Publication No. 15-05229-EF-1. 2015 Authors' objectives To assess the net balance of benefits and harms from routine use of aspirin for primary prevention across clinically relevant age, sex, and cardiovascular disease (CVD) risk groups. Authors' conclusions Benefits are predicted to exceed harms among persons aged 40-69 with nonelevated bleeding risk who take aspirin for primary prevention of CVD and CRC over their lifetimes. Net benefits from routine aspirin use over a 10- or 20-year horizon are expected to be substantially smaller, and in many cases, harms may exceed benefits. Findings do not differ markedly between men and women; however, deterministic and probabilistic sensitivity analyses reveal meaningful uncertainty about the magnitude of net benefit. Indexing Status Subject indexing assigned by CRD MeSH Aspirin; Cardiovascular Diseases; Decision Support Techniques; Humans; Neoplasms Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32015001087 Date abstract record published 27/10/2015 |